Analyst Coverage Initiated: CELU rating Buy by H.C. Wainwright
Price Target: $15
Report Date: 06-22-2022
Symbol: CELU - Celularity Inc.
Sector: Healthcare
Industry: Biotechnology
Analyst Coverage Initiated: CELU rating Buy by H.C. Wainwright
Price Target: $15
Celularity Inc. (CELU)
170 Park Avenue
Florham Park, NJ
Phone: 908 768 2170
Website: http://www.celularity.com
CEO:
NASDAQ, Nasdaq Capital Market
Celularity Inc., a clinical stage biotechnology company, develops placental-derived allogeneic cell therapies. The company offers genetically modified and unmodified NK cells; engineered T cells, including CAR-T cells; and mesenchymal-like adherent stromal cells targeting indications across cancer, immunologic, infectious, and degenerative diseases. It also offers cell therapy candidates in pre-clinical and clinical development, as well as placental-derived products for surgical use. The company was founded in 2016 and is based in Florham Park, New Jersey.
stock market signals, daily stock signals, stock trading signals services, stock market trading signals
Good stock signals have been found on this server. That is all we know.
+1 (407) 559-7228